EUVIMEDEUVIMED entdecken
Editorial

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma

Antonio Silvani iD, Enrico Franceschi

Tumori Journal · 2024

DOI: 10.1177/03008916231217583 ↗

Kurz gefasst

Editorial in der Zeitschrift Tumori Journal, 2024. Verfasst von Antonio Silvani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

, where it occurs in almost as much as 90% of cases regardless of grading, and in non-co-deleted IDH-mutant astrocytomas, where it affects approximately 35% of patients. Grade 4 glioblastomas and astrocytomas expressing the IDh mutation are a numerically tiny group. The INDIGO trial (NCT04164901) is a randomized, double-blind, controlled phase III trial. A total of 340 patients with mutant grade II gliomas were enrolled, including oligodendrogliomas and astrocytomas, and randomized (1:1) to receive vorasetinib or placebo. Patients were eligible if they were 12 years or older and had histologically confirmed grade 2 residual or recurrent oligodendroglioma or astrocytoma (according to WHO 2016 criteria) with centrally confirmed IDH1 and IDH2 mutation status. Other critical eligibility criteria included a Karnofsky performance status (KPS) score of at least 80, at least one previous surgery (with the most recent surgery occurring between one and five years before randomization), no other anticancer treatment for glioma, and no use of steroids for signs or symptoms of glioma. Of note, patients should be considered by investigators to be appropriate candidates for a watch-and-wait approach and not to be at high risk (with uncontrolled seizures, brainstem involvement, and clinically relevant functional or neurocognitive deficits caused by the tumor). Patients had measurable, non-enhancing disease assessed centrally and these were patients with non-enhancing

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaMutationPyridinesBrain NeoplasmsHumans

Stichwörter der Autor:innen

Vorasidenibisocitrate dehydrogenase (IDH)-mutant gliomanoncodeleted IDH-mutant astrocytomasoligodendroglioma

Substanzen

Isocitrate DehydrogenaseIDH2 protein, humanIDH1 protein, humanPyridines

Autor:innen und Institutionen

  • Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
  • IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.

ORCID-Profile: Antonio Silvani

Zitieren

APA

Silvani, A., & Franceschi, E. (2024). A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma. Tumori Journal. https://doi.org/10.1177/03008916231217583

Vancouver

Silvani A, Franceschi E. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma. Tumori Journal. 2024. doi:10.1177/03008916231217583

BibTeX
@article{Silvani2024,
  author = {Silvani, Antonio and Franceschi, Enrico},
  title = {A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma},
  journal = {Tumori Journal},
  year = {2024},
  doi = {10.1177/03008916231217583}
}
Kostenlos starten →